Clinical Trials and Clinical Judgment

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Clinical Trials

In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...

متن کامل

Evidence Based Medicine: Clinical Trials

Evidence based medicine is very important for success of modern medicine. It is the ongoing process of using the most reliable evidence from clinical studies, scientific understanding and medical practice to make the best possible medical choice for patients. Evidence based medicine is how medicine advances and how we get improvements in life expectancy and quality of life. It not only identifi...

متن کامل

Clinical Judgment

of Medicine and other periodicals over the past decade. Dr. Feinstein's aim is nothing less than to induce doctors to think in new ways. He hopes that one result of his proposed revolution in clinical thinking will restore to clinical medicine the status it has lost owing to the explosive growth of molecular biology. He traces at length the growth and change of clinical investigation in this co...

متن کامل

Clinical versus actuarial judgment.

Professionals are frequently consulted to diagnose and predict human behavior; optimal treatment and planning often hinge on the consultant's judgmental accuracy. The consultant may rely on one of two contrasting approaches to decision-making--the clinical and actuarial methods. Research comparing these two approaches shows the actuarial method to be superior. Factors underlying the greater acc...

متن کامل

Clinical pharmacy and clinical trials

CPC-148 Table 1 adalimumab infliximab ustekinumab Lost to follow-up 5% (1/20) 23.5% (4/17) 22% (2/9) Continuing treatment 40% (8/20) 29.4% (5/17) 67% (6/9) Withdrawal/ Discontinuation by doctor 5% (1/20) 5.9% (1/17) 11% (1/9) Discontinuation due to good response 20% (4/20) – – Change of treatment 30% (6/20) 41.2% (7/17) – The causes of the discontinuation/change of treatment were: Abstract CPC-...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of the American College of Cardiology

سال: 2008

ISSN: 0735-1097

DOI: 10.1016/j.jacc.2008.02.030